Direct acquirers for hormone replacement platforms.
Hormone replacement therapy telehealth occupies the same regulatory and processing landscape as compounded GLP-1: prescriber plus pharmacy fulfillment chain, high recurring billing exposure, banks with specific telehealth policies. Testosterone replacement, estrogen therapy, peptide HRT, and compounded hormone protocols all have placement paths at the right acquirers when the underwriting documentation is in writing.
State medical license documentation for prescribers in each operating state, telehealth platform integration documentation, fulfillment pharmacy contracts (503A or 503B compounding pharmacies plus any retail pharmacy partners), written clinical protocols, refund and discontinuation policy, marketing copy review materials.
Typical 5 to 12 percent rolling at boarding, releasing on 6-month review. FDA-approved-only platforms board lowest at 3 to 5 percent. Compounded HRT platforms can board at 10 to 15 percent if documentation is incomplete.
Stripe tokens do not transfer. Re-tokenization at the new gateway with Visa Account Updater and Mastercard ABU recovers 70 to 85 percent of pre-termination MRR within 30 days.
Peptide HRT sits in the same regulatory zone as compounded GLP-1. The 503A pharmacy compounding framework applies. Banks evaluate the prescriber plus pharmacy chain the same way.